trending Market Intelligence /marketintelligence/en/news-insights/trending/zgx-xbbowmkuo16r_txtsw2 content esgSubNav
In This List

DanDrit Biotech acquires privately held HIV therapy developer

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


DanDrit Biotech acquires privately held HIV therapy developer

DanDrit Biotech USA Inc. completed its previously announced acquisition of Enochian Biopharma Inc.

Enochian is a privately held, Los Angeles-based developer of technology platforms for the treatment of HIV. Following the acquisition, Enochian becomes a wholly owned subsidiary of DanDrit.

Additionally, DanDrit completed a private placement of 1,677,130 common shares priced at $8 each to investors outside the U.S. Some DanDrit shareholders also bought 2,400,000 common shares through an exercise of warrants.

DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.